drugset / Trial / NCT02466906
RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer
Phase 2
Unknown
60 enrolled
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is to investigate the efficacy and safety of rhGM-CSF as adjuvant immunotherapy for patients with resectable stage III colon cancers.
Timeline
- Start
- 2015-06
- Primary completion
- 2020-06
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rhGM-CSF | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |